BRIGHTCOVE
17.5.2021 01:02:07 CEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the global leader in video for business, today announced that the Melbourne Symphony Orchestra (MSO) is using Brightcove to power its new digital platform MSO.LIVE to cast the Orchestra’s 2021 season in Australia and around the world.
“Brightcove’s technology delivers a polished interface with exceptional quality of video and audio across multiple devices, to ensure we can deliver easily accessible, world-class digital experiences to all audiences,” said Sophie Galaise, Managing Director of the Melbourne Symphony Orchestra.
The MSO is a world-class orchestra with global credibility in providing enriching music experiences to audiences. MSO.LIVE offers 24-hour entertainment on-demand, live, and pre-recorded, delivering accessible and premium content as an alternative to traditional, in-person orchestral experiences. The MSO.LIVE experience is accessible, offering MSO concerts, family programming, and special events and performances from around the world.
A key driver for implementing Brightcove’s online video platform is to make performance experiences easily accessible and affordable to a wider audience, including those who are unable to attend in-person concerts.
The MSO’s main focus is to optimise its content delivery experience to retain existing orchestral music fans and attract new audiences from around the world to the MSO.LIVE platform. New performances are released monthly, and MSO.LIVE members are able to view content across devices and connected TVs.
Using Brightcove, MSO.LIVE demonstrates innovation within the Australian arts community by offering a contemporary content library personalised to audience preferences. “Among other criteria, we selected Brightcove as their local team of experts had the capabilities to integrate customer data with our CRM system,” said Ms. Galaise.
MSO.LIVE offers a range of traditional and contemporary content from both the MSO and other world-class orchestras from around the world, such as the Berliner Philharmoniker and Royal Concertgebouw Orchestra.
MSO.LIVE is priced at $15 per month or $144 per year for an annual subscription, or audiences can subscribe to a one-month pass or pay-per-view access. MSO.LIVE also offers a selection of free content, including programs for kids, audio, and more. View MSO.LIVE here .
“Our partnership with the Melbourne Symphony Orchestra demonstrates the power that video provides to the entertainment and music industry,” said Jennifer Smith, Chief Marketing Officer, Brightcove. “Brands in the Arts and Entertainment sector are embracing the hybrid model to allow them to grow their audiences to engage both in-person and online viewers. 2020 drove the urgency to pivot to new digital video experiences, and businesses are now embracing this as a long-term growth strategy. MSO.LIVE takes the orchestral experience to the next level and cements the MSO as a leader when it comes to the future of live performances,” said Smith.
As part of a longer-term strategy, the introduction of MSO.LIVE will help demonstrate Australia’s unique culture and celebrate the diverse talents of its local artists with the rest of the world.
About Melbourne Symphony Orchestra
Each year, the MSO engages with more than 5 million people through live concerts, TV, radio and online broadcasts, international and regional tours, recordings and education programs.
The MSO is a vital presence, both onstage and in the community, in cultivating classical music in Australia. Internationally acclaimed, the Orchestra nurtures strong cultural partnerships throughout South-East Asia. The MSO is the only Australian orchestra partnered with UNITEL, the world’s leading distributor of classical music programs for film, television and video.
The MSO regularly attracts great artists from around the globe, including Anne-Sophie Mutter, Lang Lang, Renée Fleming and Nick Cave, while bringing Melbourne’s finest musicians to the world through tours to China, Indonesia, Europe and the United States.
The nation’s first professional orchestra, the Melbourne Symphony Orchestra has been the sound of the city of Melbourne since 1906. www.mso.com.au .
About Brightcove Inc.
When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organisations in more than 70 countries across the globe to touch audiences in bold and innovative ways.
Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business™
View source version on businesswire.com: https://www.businesswire.com/news/home/20210516005011/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom